Your browser is no longer supported. Please, upgrade your browser.
ATNX Athenex, Inc. daily Stock Chart
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.46 Insider Own7.10% Shs Outstand81.56M Perf Week-8.47%
Market Cap1.09B Forward P/E- EPS next Y-1.31 Insider Trans44.66% Shs Float59.95M Perf Month-3.05%
Income-116.40M PEG- EPS next Q-0.43 Inst Own54.20% Short Float16.23% Perf Quarter-2.55%
Sales140.80M P/S7.76 EPS this Y8.10% Inst Trans6.38% Short Ratio12.00 Perf Half Y20.40%
Book/sh1.71 P/B6.70 EPS next Y20.60% ROA-39.00% Target Price- Perf Year8.22%
Cash/sh1.22 P/C9.39 EPS next 5Y- ROE-72.20% 52W Range5.63 - 18.35 Perf YTD-25.02%
Dividend- P/FCF- EPS past 5Y-39.10% ROI-49.90% 52W High-37.60% Beta0.85
Dividend %- Quick Ratio2.80 Sales past 5Y142.30% Gross Margin39.40% 52W Low103.37% ATR0.58
Employees574 Current Ratio3.20 Sales Q/Q81.10% Oper. Margin-78.10% RSI (14)43.97 Volatility4.53% 4.40%
OptionableYes Debt/Eq0.69 EPS Q/Q-13.20% Profit Margin-82.60% Rel Volume0.62 Prev Close11.91
ShortableYes LT Debt/Eq0.68 EarningsNov 05 BMO Payout- Avg Volume811.11K Price11.45
Recom1.70 SMA20-6.97% SMA50-5.57% SMA200-1.89% Volume499,533 Change-3.86%
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Oct-25-20 07:05AM  
Oct-22-20 07:00AM  
Oct-14-20 09:51PM  
Oct-12-20 04:05PM  
Oct-09-20 07:30AM  
Oct-06-20 07:34AM  
Sep-23-20 07:00AM  
Sep-19-20 07:00AM  
Sep-10-20 01:59PM  
07:00AM  
Sep-08-20 04:01PM  
07:00AM  
Sep-06-20 10:03AM  
Sep-02-20 01:24PM  
10:40AM  
Sep-01-20 12:58PM  
10:46AM  
07:00AM  
Aug-07-20 09:02AM  
Aug-06-20 12:15PM  
07:00AM  
07:00AM  
Aug-04-20 09:30AM  
Jul-27-20 07:00AM  
Jul-08-20 09:24AM  
Jun-29-20 11:41AM  
Jun-27-20 09:28PM  
Jun-23-20 07:00AM  
Jun-22-20 08:00AM  
Jun-13-20 10:00AM  
Jun-08-20 06:19PM  
Jun-03-20 04:50PM  
Jun-02-20 06:12AM  
May-29-20 08:00AM  
May-27-20 12:40PM  
08:40AM  
May-25-20 03:45PM  
May-19-20 09:05AM  
May-12-20 12:00PM  
11:29AM  
May-09-20 01:31PM  
May-08-20 12:41PM  
May-07-20 06:47PM  
09:47AM  
08:45AM  
07:00AM  
Apr-30-20 12:34PM  
Apr-29-20 01:54PM  
Apr-23-20 08:00AM  
Apr-09-20 07:00AM  
Mar-13-20 08:10AM  
Mar-11-20 07:06AM  
Mar-10-20 07:05PM  
Mar-09-20 07:00AM  
Mar-06-20 12:00PM  
Mar-02-20 10:19AM  
Feb-27-20 10:15AM  
07:00AM  
06:00AM  
Feb-25-20 08:00AM  
Feb-20-20 12:31PM  
Feb-06-20 07:00AM  
Feb-03-20 05:01PM  
Jan-16-20 09:46AM  
05:58AM  
Jan-08-20 01:51PM  
Dec-28-19 05:17PM  
Dec-27-19 02:57PM  
Dec-22-19 01:52PM  
Dec-16-19 07:00AM  
Dec-13-19 09:46AM  
09:31AM  
08:30AM  
Dec-11-19 07:00AM  
Dec-09-19 08:10PM  
Dec-05-19 08:00AM  
Dec-02-19 05:00AM  
Nov-21-19 08:42AM  
Nov-19-19 09:05AM  
Nov-18-19 03:29AM  
Nov-07-19 08:35AM  
07:00AM  
Oct-31-19 10:34AM  
Oct-30-19 07:00AM  
Oct-28-19 03:30AM  
Oct-26-19 12:33PM  
Oct-24-19 07:00AM  
07:00AM  
Oct-21-19 04:46PM  
11:29AM  
Oct-18-19 06:49AM  
Oct-10-19 10:34PM  
Oct-07-19 12:14PM  
Sep-30-19 11:44AM  
Sep-23-19 07:00AM  
07:00AM  
07:00AM  
Sep-22-19 04:44PM  
Sep-13-19 05:15AM  
Sep-12-19 07:15AM  
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 24Buy11.951,00011,9503,145,959Sep 24 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 21Buy12.421,00012,4203,144,959Sep 21 04:53 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 14Buy11.001,800,00019,800,00013,532,467Sep 14 03:47 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 14Buy11.951,00011,9503,143,959Sep 14 04:09 PM
Fok MansonDirectorSep 12Buy11.0316,491181,8961,999,609Sep 14 04:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.911,00010,9103,142,959Sep 14 04:09 PM
Fok MansonDirectorSep 11Buy11.3913,509153,8681,983,118Sep 14 04:21 PM
WU JINNDirectorSep 11Buy11.0510,000110,500401,208Sep 14 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.992,00021,9783,141,959Sep 11 04:10 PM
YORDON JEFFREYSee RemarksSep 10Option Exercise11.0018,180199,980237,106Sep 10 04:44 PM
Davis Stephanie ADirectorSep 10Buy11.3510,000113,50020,000Sep 14 04:24 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 10Buy11.24200,0002,248,00011,732,467Sep 14 03:47 PM
Kanfer JordanDirectorSep 10Buy11.494505,1714,634Sep 11 04:20 PM
WU JINNDirectorSep 10Buy11.1520,000223,000391,208Sep 11 04:16 PM
Sze RandollChief Financial OfficerSep 10Buy11.401,00011,4006,000Sep 10 04:48 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 10Buy11.2210,000112,2003,139,959Sep 10 04:38 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 21Option Exercise4.555,00022,7503,129,959Aug 21 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 20Option Exercise4.5510,00045,5003,124,959Aug 20 04:14 PM
Kwan RudolfEVP, Chief Medical OfficerJun 22Buy12.821,00012,820143,299Jun 23 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardJun 22Buy12.812,00025,6203,114,959Jun 22 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 27Buy7.881,0007,8803,112,959Mar 27 04:30 PM
Sze RandollChief Financial OfficerMar 27Buy8.191,0008,1905,000Mar 27 04:14 PM
Fok MansonDirectorMar 25Buy7.2550,000362,5001,969,609Mar 26 05:07 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 23Buy6.641,0006,6403,111,959Mar 23 04:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 20Buy6.851,0006,8503,110,959Mar 20 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Buy6.602,00013,2003,109,959Mar 19 04:14 PM
Kwan RudolfEVP, Chief Medical OfficerMar 18Buy5.904,00023,584141,048Mar 19 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 18Buy5.782,00011,5603,107,959Mar 18 04:11 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Buy6.902,00013,8003,105,959Mar 17 04:42 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 16Buy7.612,00015,2203,103,959Mar 16 04:11 PM
TSANG Benson Kwan HungDirectorMar 13Buy8.395,00041,95010,000Mar 16 06:55 AM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.354,00033,3963,099,959Mar 12 04:11 PM
Kwan RudolfEVP, Chief Medical OfficerMar 12Buy8.192,00016,380137,048Mar 13 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.122,00016,2403,101,959Mar 13 04:13 PM
YORDON JEFFREYSee RemarksMar 12Buy8.1410,00081,430218,926Mar 12 04:15 PM
TSANG Benson Kwan HungDirectorMar 12Buy8.345,00041,7005,000Mar 13 05:23 PM
Fok MansonDirectorMar 11Buy10.2850,000513,8501,919,609Mar 11 04:21 PM
Kwan RudolfEVP, Chief Medical OfficerMar 09Buy9.792,00019,573135,048Mar 10 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 24Buy14.3973,6981,060,51411,532,467Dec 27 04:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 23Buy14.30153,2372,191,28911,458,769Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 20Buy14.14189,3222,677,01311,305,532Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 19Buy13.78263,7433,635,48411,116,210Dec 26 06:04 AM
WU JINNDirectorDec 18Option Exercise4.5520,00091,000371,208Dec 19 04:09 PM
Sze RandollChief Financial OfficerDec 17Buy13.251,00013,2504,000Dec 17 04:11 PM
WU JINNDirectorDec 16Option Exercise4.5530,000136,500351,208Dec 18 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 16Option Exercise4.5515,00068,2503,095,959Dec 17 04:08 PM
Fok MansonDirectorNov 07Buy11.6750,000583,5001,869,609Nov 12 04:06 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.